Monopar Therapeutics (MNPR) Operating Leases (2022 - 2026)

Monopar Therapeutics (MNPR) posted Operating Leases of $154920.0 for Q4 2025, up 118.56% sequentially from $70881.0 in Q3 2025.

Analysis

Monopar Therapeutics (MNPR) Operating Leases (2022 - 2026) Analysis & Trends

Monopar Therapeutics has reported Operating Leases for 2 years, with the latest figure at $154920.0 in Q4 2025.

Quarterly Operating Leases changed N/A year-over-year to $154920.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $154920.0 (changed N/A YoY) and the FY2025 annual result came in at $154920.0, changed N/A from the prior year.
Operating Leases grew to $154920.0 in Q4 2025 per MNPR's latest filing, from $70881.0 in the prior quarter.
Over five years, Operating Leases peaked at $154920.0 in Q4 2025 and troughed at $8408.0 in Q4 2022.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn
8	Royalty Pharma	28.45 Bn	27.61 Bn	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn
10	Monopar Therapeutics	1.01 Bn	954.06 Mn	-

Historic Data

Download Data